Show source-provided references
8. Recent advances in cell membrane coated metal-organic frameworks (MOFs) for tumor therapy
10.1039/D1TB00453K ↗10. Wu, X., Li, Y., Raza, F., Wang, X., Zhang, S., Rong, R., Qiu, M., and Su, J. (2021). Red Blood Cell Membrane-Camouflaged Tedizolid Phosphate-Loaded PLGA Nanoparticles for Bacterial-Infection Therapy. Pharmaceutics, 13.
10.3390/pharmaceutics13010099 ↗13. Zhu, Y., Xu, L., Kang, Y., Cheng, Q., He, Y., and Ji, X. (2024). Platelet-derived drug delivery systems: Pioneering treatment for cancer, cardiovascular diseases, infectious diseases, and beyond. Biomaterials, 306.
10.1016/j.biomaterials.2024.122478 ↗25. Mandel, J., Casari, M., Stepanyan, M., Martyanov, A., and Deppermann, C. (2022). Beyond Hemostasis: Platelet Innate Immune Interactions and Thromboinflammation. Int. J. Mol. Sci., 23.
10.3390/ijms23073868 ↗26. Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases
10.1124/pr.117.014530 ↗32. Johnson, K.E., McAllister, S.S., Italiano, J.E., and Battinelli, E.M. (2022). The Role of Platelets in the Tumor Microenvironment. Biomarkers of the Tumor Microenvironment, Springer.
34. Yu, L., Guo, Y., Chang, Z., Zhang, D., Zhang, S., Pei, H., Pang, J., Zhao, Z.J., and Chen, Y. (2021). Bidirectional Interaction Between Cancer Cells and Platelets Provides Potential Strategies for Cancer Therapies. Front. Oncol., 11.
10.3389/fonc.2021.764119 ↗45. Hu, C., Long, L., Lou, J., Leng, M., Yang, Q., Xu, X., and Zhou, X. (2024). CTC-neutrophil interaction: A key driver and therapeutic target of cancer metastasis. Biomed. Pharmacother., 180.
10.1016/j.biopha.2024.117474 ↗47. Neutrophil Nanodecoys Inhibit Tumor Metastasis by Blocking the Interaction between Tumor Cells and Neutrophils
10.1021/acsnano.3c08946 ↗49. Lysis of tumor cells by natural killer cells in mice is impeded by platelets
50. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity
10.1158/0008-5472.CAN-09-2123 ↗51. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells
10.1158/0008-5472.CAN-11-1872 ↗55. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: Results from the Vienna Cancer and Thrombosis Study (CATS)
10.1182/blood-2008-02-142422 ↗56. Rethinking the war on cancer
60. Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets
10.1124/mol.112.083477 ↗62. Fang, M., Liu, R., Fang, Y., Zhang, D., and Kong, B. (2024). Emerging platelet-based drug delivery systems. Biomed. Pharmacother., 177.
10.1016/j.biopha.2024.117131 ↗64. Platelet collagen receptors and their role in modulating platelet adhesion patterns and activation on alternatively processed collagen substrates
10.1016/j.thromres.2024.109201 ↗65. Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell-derived ADAM9
66. Tumors and Fibrinogen
68. Single-molecule binding of CD44 to fibrin versus P-selectin predicts their distinct shear-dependent interactions in cancer
10.1242/jcs.079814 ↗70. Xu, P., Zuo, H., Chen, B., Wang, R., Ahmed, A., Hu, Y., and Ouyang, J. (2017). Doxorubicin-loaded platelets as a smart drug delivery system: An improved therapy for lymphoma. Sci. Rep., 7.
10.1038/srep42632 ↗75. pH-responsive hybrid platelet membrane-coated nanobomb with deep tumor penetration ability and enhanced cancer thermal/chemodynamic therapy
10.7150/thno.68996 ↗76. Magnetic Metal-Organic Framework-Based Nanoplatform with Platelet Membrane Coating as a Synergistic Programmed Cell Death Protein 1 Inhibitor against Hepatocellular Carcinoma
10.1021/acsnano.3c07885 ↗78. Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy
10.1038/s41551-018-0310-2 ↗80. Glycopolymeric Micellar Nanoparticles for Platelet-Mediated Tumor-Targeted Delivery of Docetaxel for Cancer Therapy
10.1021/acsami.4c09548 ↗82. Wang, H., Wu, J., Williams, G.R., Fan, Q., Niu, S., Wu, J., Xie, X., and Zhu, L.M. (2019). Platelet-membrane-biomimetic nanoparticles for targeted antitumor drug delivery. J. Nanobiotechnol., 17.
10.1186/s12951-019-0494-y ↗86. Platelet-Membrane-Coated Nanoparticles Enable Vascular Disrupting Agent Combining Anti-Angiogenic Drug for Improved Tumor Vessel Impairment
10.1021/acs.nanolett.1c00168 ↗88. Platelet Membrane-Camouflaged Magnetic Nanoparticles for Ferroptosis-Enhanced Cancer Immunotherapy
10.1002/smll.202001704 ↗90. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets
10.1038/s41551-021-00712-1 ↗91. Platelets camouflaged nanovehicle improved bladder cancer immunotherapy by triggering pyroptosis
10.7150/thno.99040 ↗92. Platelet membrane biomimetic nanomedicine induces dual glutathione consumption for enhancing cancer radioimmunotherapy
10.1016/j.jpha.2024.01.003 ↗94. Targeted gene silencing in vivo by platelet membrane-coated metal-organic framework nanoparticles
10.1126/sciadv.aaz6108 ↗95. Platelet-Like Fusogenic Liposome-Mediated Targeting Delivery of miR-21 Improves Myocardial Remodeling by Reprogramming Macrophages Post Myocardial Ischemia-Reperfusion Injury
10.1002/advs.202100787 ↗96. Camouflaged Hybrid Cancer Cell-Platelet Fusion Membrane Nanovesicles Deliver Therapeutic MicroRNAs to Presensitize Triple-Negative Breast Cancer to Doxorubicin
10.1002/adfm.202103600 ↗98. Platelet-mimicking nanoparticles co-loaded with W(18)O(49) and metformin alleviate tumor hypoxia for enhanced photodynamic therapy and photothermal therapy
10.1016/j.actbio.2018.09.017 ↗99. NIR light-induced tumor phototherapy using ICG delivery system based on platelet-membrane-camouflaged hollow bismuth selenide nanoparticles
10.1016/j.cclet.2019.10.040 ↗100. Platelet-membrane-camouflaged bismuth sulfide nanorods for synergistic radio-photothermal therapy against cancer
10.1039/C9BM00599D ↗